Corcept Therapeutics
CORT
389 hedge funds and large institutions have $2.67B invested in Corcept Therapeutics in 2025 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 119 increasing their positions, 157 reducing their positions, and 95 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0.46% less ownership
Funds ownership: 73.25% → 72.79% (-0.46%)
9% less funds holding
Funds holding: 429 → 389 (-40)
24% less repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 157
35% less first-time investments, than exits
New positions opened: 62 | Existing positions closed: 95
58% less capital invested
Capital invested by funds: $6.41B → $2.67B (-$3.74B)
69% less call options, than puts
Call options by funds: $57.1M | Put options by funds: $187M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$59M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$57.7M |
| 3 |
Morgan Stanley
New York
|
+$31.8M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$21.1M |
| 5 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$19.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
-$51.4M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$48.6M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$43.8M |
| 4 |
SAM
Synergy Asset Management
Vancouver,
Washington
|
-$39.6M |
| 5 |
ISL
Ingalls & Snyder LLC
New York
|
-$39.5M |
CORT Hedge Fund Activity: Q4 2025 in Review
389 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2025, worth a combined $2.67B — down 58% from $6.41B a quarter earlier.
Sellers outnumbered buyers: 95 funds closed out of CORT and 62 opened new positions — a net loss of 33 holders — while 157 trimmed existing stakes and 119 added.
The largest buyer was Citadel Advisors, adding an estimated $59M. The largest seller was ClearBridge Investments, cutting an estimated $51.4M.
- 389 institutional investors held Corcept Therapeutics (CORT) as of Q4 2025, down from 429 in Q3 2025.
- Funds reported $2.67B of Corcept Therapeutics stock for Q4 2025, down 58% quarter-over-quarter.
- 62 funds opened new Corcept Therapeutics positions in Q4 2025 and 95 closed out, a net change of -33 holders.
- The largest Corcept Therapeutics buyer in Q4 2025 was Citadel Advisors, an estimated $59M added.
- The largest Corcept Therapeutics seller in Q4 2025 was ClearBridge Investments, an estimated $51.4M sold.
Based on aggregated 13F filings for Q4 2025.